Nasal sprays are utilized to deliver drugs to the nasal cavities, either locally or systemically. They are effective in treating conditions like allergic rhinitis and nasal congestion. By administering medication nasally, it is absorbed through the nasal mucosa instead of entering the respiratory tract. This method offers a non-invasive approach for both local and systemic therapy, particularly beneficial for medications prone to high metabolism or instability in the gastrointestinal tract.
The growing prevalence of allergic rhinitis is anticipated to stimulate the expansion of the market during the projected timeframe. The advantages associated with nasal sprays are projected to enhance the growth of the nasal spray market in the United States over the forecast period. The utilization of the nasal route for drug delivery and the numerous benefits it offers are expected to drive the growth of the U.S. nasal spray market during the forecast period.
The projected worth of the US Nasal Spray Market is approximately US$ 9,272.8 million by 2022, with a predicted compound annual growth rate (CAGR) of 6.8% from 2022 to 2030.
Top Companies in the U.S. Nasal Spray Industry:
- GlaxoSmithKline plc.
GlaxoSmithKline Plc. was established in 2000 and is headquartered in Brentford, United Kingdom. It has operations in more than 100 countries and is engaged in various industries, including biotechnology, healthcare, and pharmaceuticals. In 2020, GlaxoSmithKline (GSK) launched a natural saline nasal spray for the relief of hay fever and other allergy symptoms in its Piri range.
- Merck & Co., Inc.
Merck & Co. was established in 1891 and is headquartered in Rahway, New Jersey, United States. It operates in over 191 countries and is engaged in developing medicines, vaccines, biologic therapies, and animal health products.
- Novartis AG
Novartis AG was established in 1996 and is headquartered in Basel, Switzerland. It has operations in 140 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceutical. In 2020, Novartis AG received a positive CHMP opinion for the new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps.
- Pfizer Inc.
Pfizer Inc. was established in 1849 and is headquartered in New York, United States. It operates in 181 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals. In 2023, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) had approved ZAVZPRET™, the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray.
- Procter & Gamble
Procter & Gamble was established in 1837 and is headquartered in Cincinnati, Ohio, U.S. It operates in 70 countries and is engaged in various industries, including food and beverage and consumer goods.
- AstraZeneca Plc.
AstraZeneca Plc. was established in 1999 and is headquartered in Cambridge, United Kingdom. It operates in over 100 countries and is engaged in various industries, including biopharma, biotechnology, healthcare, medical, and pharmaceutical.
- Sanofi S.A.
Sanofi S.A. was established in 1973 and is headquartered in Paris, France. It operates in over 100 countries and is engaged in various industries, including healthcare, life science, pharmaceuticals, and therapeutics.
- Bayer AG
Bayer AG was established in 1863 and is headquartered in Leverkusen, Germany. It operates in over 80 countries and is engaged in various industries, including biotechnology, chemicals, healthcare, life science, and pharmaceuticals.
Definition: Nasal sprays are liquid medications delivered through the nose to treat congestion, allergies, or sinus-related conditions.
